Hint mode is switched on Switch off

SpyGlass Pharma, ordinary share
SGP, US85220G1094

Add a stock to WL
Choose all Reset all
SpyGlass Pharma, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug ...
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    SpyGlass Pharma, Inc.
  • Industry
    Medical Devices

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    SGP
  • Placement
    06.02.2026
  • Lock up period
    180
  • Number of papers
    9,375,000
  • Volume of raised funds
    150 mln USD
  • Placement share
    29.38%
  • Final placement price
    16 USD
  • Price change since placement date
    49.81%
  • By capitalization
    510.58 mln USD

IFRS/US GAAP reports

2026
I q eng
2025
IV q eng
Show all Hide

Related Stock indices

Indicators

News

26/03/2026 SpyGlass Pharma: Results Of Operations And Financial Condition, Financial Statements And Exhibits
09/03/2026 SpyGlass Pharma: Other Events, Financial Statements And Exhibits
12/02/2026 SpyGlass Pharma: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
05/02/2026 SpyGlass Pharma: On This Form 8k, Including Exhibit 99.1 Attached Hereto, Shall Not Be Deemed “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference Into Any Other Filing Under The Securities Act Or The Exchange Act, Except As Expressly Set Forth By Specific Reference In Such A Filing, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.